article = {COR-2020-7-105}
title = {Treating Acute Myeloid Leukemia in Patients Presenting with COVID-19}
journal = {Clinical Oncology and Research}
year = {2020}
issn = {2613-4942}
doi = {http://dx.doi.org/10.31487/j.COR.2020.07.05}
url = {https://www.sciencerepository.org/treating-acute-myeloid-leukemia-in-patients-presenting-with-covid-19_COR-2020-7-105 
author = {Rutger  Callens,Dieter  Stevens,Sebastiaan  Dhont,Elise  Peys,Ine Moors,}
keywords = {acute myeloid leukemia, COVID-19, IDH1/2-inhibitors, FLT3-inhibitors, hypomethylating agents, treatment discontinuation}
abstract ={Patients with hematological malignancies are at increased risk for severe COVID-19 with a high mortality
rate. In AML, more and more patients are treated on an outpatient basis. This gives rise to two dilemmas
in the face of COVID-19. The first one is whether to temporarily interrupt the oral antileukemia treatment
and the second one is which patients should be intubated. Here, we describe our institutional approach and
the underlying rationale in patients on lower intensity treatments for AML presenting with COVID-19}